Neoadjuvant Chemo-radiotherapy

PreclinicalSmall molecule

Neoadjuvant Chemo-radiotherapy is one of 4 small molecule programs targeting Hilar Cholangiocarcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hilar CholangiocarcinomaActive, not recruiting

Hilar CholangiocarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Hilar Cholangiocarcinoma

#DrugCompanyPhaseTrials

Adrucil

EElorac, Inc.

Approved

—2

Photofrin

PPinnacle Biologics Inc.

Approved

—3

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Preclinical

1 4

Neoadjuvant Chemo-radiotherapy

HHospital Vall d'Hebron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Recruiting

Hilar Cholangiocarcinoma

NCT04378023

Clinical

Trials by Indication[1]

Hilar Cholangiocarcinoma1 trial

Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.

Recruiting·HHospital Vall d'Hebron··NCT04378023·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Neoadjuvant Chemo-radiotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoadjuvant Chemo-radiotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoadjuvant Chemo-radiotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Vall d'Hebron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHospital Vall d'Hebron

Neoadjuvant Chemo-radiotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Hilar Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News